Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer

Journal of the National Cancer Institute

Volumn 95, Issue 13, 2003, Pages 990-1000

  Denmeade, Samuel R ^a   Jakobsen, Carsten M ^b   Janssen, Samuel ^a   Khan, Saeed R ^a   Garrett, Elizabeth S ^a   Lilja, Hans ^c   Christensen, S Brogger ^b   Isaacs, John T ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CALCIUM ION; CYTOTOXIC AGENT; PRODRUG; PROSTATE SPECIFIC ANTIGEN; PROTEINASE; THAPSIGARGIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CALCIUM CELL LEVEL; CANCER CELL; CANCER CELL CULTURE; CELL CYCLE G0 PHASE; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; CHEMICAL MODIFICATION; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; DISEASE MODEL; DOSE RESPONSE; DRUG ACTIVATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG MECHANISM; DRUG SELECTIVITY; DRUG STABILITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME SUBSTRATE; GROWTH INHIBITION; HUMAN; HUMAN CELL; HYDROLYSIS KINETICS; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; KIDNEY CARCINOMA; LD 50; LIPOPHILICITY; MALE; METASTASIS POTENTIAL; MITOSIS INHIBITION; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT FAILURE; TUMOR GROWTH; TUMOR XENOGRAFT;

EID: 0042308774     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/95.13.990     Document Type: Article

References (41)

1. Isaacs JT. The biology of hormone refractory prostate cancer: why does it develop? In: Urologic clinics of North America. Vol. 26. Philadelphia (PA): W. B. Saunders; 1999. p. 263-73.
2. Kyprianou N, English HF, Isaacs JT. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res 1990;50:3748-53.
3. Samson DJ, Seidenfeld J, Schmitt B, Hasselblad V, Albertsen PC, Bennett CL, et al. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 2002;95:361-76.
4. Kyprianou N, Isaacs JT. Thymine-less death in androgen independent prostatic cancer cells. Biochem Biophys Res Commun 1989;165:73-81.
5. Martikainen P, Kyprianou N, Tucker RW, Isaacs JT. Programmed death of nonproliferating androgen-independent prostatic cancer cells. Cancer Res 1991;51:4693-700.
6. Furuya Y, Lundmo P, Short AS, Gill DL, Isaacs JT. The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin. Cancer Res 1994;54:6167-75.
7. Furuya Y, Krajewski S, Epstein JI, Reed JC, Isaacs JT. Expression of bcl-2 and the progression of human and rodent prostatic cancers. Clin Cancer Res 1996;2:389-98.
8. Tombal B, Denmeade SR, Isaacs JT. Supramicromolar elevation of intracellular calcium precedes the execution phase of apoptosis in cancer cells. Cell Death Differ 2002;9:561-73.
9. Kyprianou N, English HF, Isaacs JT. Activation of a Ca2+-Mg2+-dependent endonuclease as an early event in castration-induced prostatic cell death. Prostate 1988;13:103-17.
10. Connor J, Sawczuk IS, Benson MC, Tomasahefsky P, O'Toole KM, Olsson CA, et al. Calcium channel antagonists delay regression of androgen-independent tissues and suppress gene activity associated with cell death. Prostate 1988;13:119-30.
11. Martikainen P, Isaacs J. Role of calcium in the programmed death of rat prostatic glandular cells. Prostate 1990;17:175-87.
12. Rasmussen U, Broogger Christensen S, Sandberg F. Thapsigargine and thapsigargicine, two new histamine liberators from Thapsia garganica L. Acta Pharm Suec 1978;15:133-40.
13. Thastrup O, Cullen PJ, Drøbak BK, Hanley MR, Dawson AP. Thapsigargin, a tumor promoter, discharges intracellular Ca2+ stores by specific inhibition of the endoplasmic reticulum Ca2+-ATPase. Proc Natl Acad Sci U S A 1990;87:2466-70.
14. Davidson GA, Varhol RZ. Kinetics of thapsigargin-Ca(2+)-ATPase (sarcoplasmic reticulum) interaction reveals a two-step binding mechanism and picomolar inhibition. J Biol Chem 1995;270:11731-4.
15. Randriamampita C, Tsien RY. Emptying of intracellular Ca2+ stores releases a novel small messenger that stimulates Ca2+ influx. Nature 1993; 364:809-14.
16. Tombal B, Denmeade SR, Isaacs JT. Assessment and validation of a microinjection method for kinetic analysis of [Ca2+]i in individual cells undergoing apoptosis. Cell Calcium 1999;25:19-28.
17. Lin XS, Denmeade SR, Cisek L, Isaacs JT. The role of growth arrest in programmed (apoptotic) death of prostate cancer cells by thapsigargin. Prostate 1997;33:201-7.
18. Furuya Y, Isaacs JT. Proliferation-dependent vs. independent programmed cell death of prostatic cancer cells involves distinct gene regulation. Prostate 1994;25:301-9.
19. Tombal B, Weeraratna AT, Denmeade SR, Isaacs JT. Thapsigargin induces a calmodulin/calcineurin-dependent apoptotic cascade responsible for the death of prostatic cancer cells. Prostate 2000;43:303-17.
20. Wang HG, Pathan N, Ethell IM, Krajewski S, Yamaguchi Y, Shibasaki F, et al. Ca2+-induced apoptosis through calcineurin dephosphorylation of BAD. Science 1999;284:339-43.
21. Denmeade SR, Lin XS, Tombal B, Isaacs JT. Inhibition of caspase activity does not prevent the signaling phase of apoptosis in prostate cancer cells. Prostate 1999;39:269-79.
22. Pinski J, Parikh A, Bova S, Isaacs JT. Therapeutic implications of enhanced G0/G1 checkpoint control induced by coculture of prostate cancer cells with osteoblasts. Cancer Res 2001;61:6372-6.
23. Furuya Y, Berges RS, Lundmo P, Isaacs JT. Proliferation independent activation of programmed cell death as a novel therapy for prostate cancer. In: Mihich E, Schimmke RT, editors. Apoptosis. New York (NY): Plenum Press; 1994. p.137-56.
24. Akiyama K, Nakamura T, Iwanaga S, Hara M. The chymotrypsin-like activity of human prostate-specific antigen, gamma-seminoprotein. FEBS Lett 1987;225:168-72.
25. Christensson A, Laurell CB, Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine protease inhibitors. Eur J Biochem 1990;194:755-65.
26. Lilja H, Christensson A, Dahlen U, Matikainen MT, Nilsson O, Pettersson K, et al. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem 1991;37:1618-25.
27. Denmeade SR, Isaacs JT. Enzymatic activation of prodrugs by prostate-specific antigen: targeted therapy for metastatic prostate cancer. Cancer J Sci Am 1998;4 Suppl 1:S15-21.
28. Denmeade SR, Lou W, Lovgren J, Malin J, Lilja H, Isaacs JT. Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen. Cancer Res 1997;57:4924-30.
29. Denmeade SR, Sokoll LJ, Chan DW, Khan SR, Isaacs JT. Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostatic cancer xenograft models. Prostate 2001;48:1-6.
30. Christensen SB, Andersen A, Kromann H, Treiman M, Tombal B, Denmeade SR, et al. Thapsigargin analogues for targeting programmed death of androgen-independent prostate cancer cells. Bioorg Med Chem 1999;7: 1273-80.
31. Jakobsen CM, Denmeade SR, Isaacs JT, Gady A, Olsen CE, Christensen SB. Design, synthesis, and pharmacological evaluation of thapsigargin analogues for targeting apoptosis to prostatic cancer cells. J Med Chem 2001; 44:4696-4703.
32. Denmeade SR, Nagy A, Gao J, Lilja H, Schally A, Isaacs JT. Enzymatic-activation of a doxorubicin-peptide prodrug by prostate-specific antigen. Cancer Res 1998;58:2537-40.
33. Khan SR, Denmeade SR. In vivo activity of a PSA-activated doxorubicin prodrug against PSA-producing human prostate cancer xenografts. Prostate 2000;45:80-3.
34. Telford WG, Komoriya A, Packard BZ. Detection of localized caspase activity in early apoptotic cells by laser scanning cytometry. Cytometry 2002;47:81-8.
35. Pinski J, Weeraratna A, Uzgare AR, Arnold JT, Denmeade SR, Isaacs JT. Trk receptor inhibition induces apoptosis of proliferating but not quiescent human osteoblasts. Cancer Res 2002;62:986-9.
36. Berges RS, Vukanovic J, Epstein JI, Carmichel M, Cisek L, Johnson DE, et al. Implication of the cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res 1995;1:473-80.
37. Vukanovic J, Isaacs JT. Human prostatic cancer cells are sensitive to programmed (apoptotic) death induced by the antiangiogenic agent linomide. Cancer Res 1995;55:3517-20.
38. Gibaldi M, Perrier D, editors. Pharmacokinetics. 2nd ed. New York (NY): Marcel Dekker; 1982. p. 409-17.
39. DeFeo-Jones D, Garsky VM, Wong BK, Feng DM, Bolyar T, Haskell K, et al. A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo. Nat Med 2000;6:1248-52.
40. Wong BK, DeFeo-Jones D, Jones RE, Garsky VM, Feng DM, Oliff A, et al. PSA-specific and non-PSA-specific conversion of a PSA-targeted peptide conjugate of doxorubicin to its active metabolites. Drug Metab Dispos 2001;29:313-8.
41. DiPaola RS, Rinehart J, Nemunaitis J, Ebbinghaus S, Rubin E, Capanna T, et al. Characterization of a novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with prostate cancer. J Clin Oncol 2002;20:1874-9.